Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Galloway, Pamela De Silva, Ulrike K. Buchwald(Merck & Co., Inc., Rahway, NJ, USA (United States)), Helena Hervius Askling(Stockholm County Council), Jung‐Hyun Choi(Catholic University of Korea), Weifeng Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth A Barranco-Santana(Ponce Health Sciences University), Walter A. Orenstein(Emory University), Charles P. Andrews(Biogen (United States)), Enrique Pelayo(Advanced Medical Research Institute), Hee Jung Choi, David Butuk, James H. Bergthold, Erik Buntinx, Diego Garcia‐Huidobro(Pontificia Universidad Católica de Chile), Leslie Morgan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Valentine M. Ebuh(Target (United States)), William Fitzgibbons(Skyline College), Young Hwa Choi(Ajou University), Luis I. De La Cruz, Folke Sjöberg(Linköping University Hospital), Larry M. Bush, Won Suk Choi(International Vaccine Institute), Oliver A. Cornely(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Olaf Degen(Universität Hamburg), Jeffrey B. Baker, Mira Baron(Palm Beach Neurology), Christopher Bruno(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey Adelglass, Joon Young Song(Korea University), Sady Alpizar, Doreen Fernsler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carlos G. Grijalva(Vanderbilt University Medical Center), Thomas Fiel, Stanton R. Elzi, Jianing Li(Northeast Agricultural University), Muhammad Waleed(King Edward Medical University), James R. Clark, Neil J. Fraser(University of Alabama at Birmingham), John Beckes, Edgardo F. Cartagena Ayala, Michael Abdel-Malek, George Hartley Freeman, Nizar Daboul, Peter Bosson, Steve E. Cox, Duane C. Anderson
The Lancet Infectious Diseases
July 1, 2024
Cited by 59


Related Papers